Tamás Solymosi
Tamás Solymosi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Réka Angi
NanGenex Inc., 47-49 Madarász Viktor u., Budapest, 1138, Hungary
8 shared publicationsZsolt Ötvös
NanGenex Inc., 47-49 Madarász Viktor u., Budapest, 1138, Hungary
8 shared publicationsGábor Heltovics
Druggability Technologies Holdings Ltd., Level 2, Regional Business Centre, University Heights, Msida, MSD 1751, Malta
6 shared publications- Hristos Glavinas
NanGenex Inc., 47-49 Madarász Viktor u., Budapest H-1138, Hungary
6 shared publications Tamás Jordán
NanGenex Inc., 47-49 Madarász Viktor u., Budapest, 1138, Hungary
6 shared publicationsOrsolya Basa-Dénes
NanGenex Inc., 47-49 Madarász Viktor u., Budapest, 1138, Hungary
5 shared publications
Latest Publications
- 10 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
Are we selecting the right model compounds for advanced formulation research?
- 10 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
Are we selecting the right model compounds for advanced formulation research?
- Open Access
- 15 April 2025
- Published by MDPI AG in Therapeutics
- Vol. 2 (2) , 6
Triacetyl-5-Azacytidine Suppresses Experimental Allergic Encephalomyelitis (EAE) in Mice
Background/Objectives: The epigenetic drug 5-azacytidine (AzaC) is being used for the treatment of myeloproliferative diseases. It has multiple immunomodulating activities: it enhances the activity of Treg cells and suppresses effector T cell proliferation and function. Our aim was to repurpose AzaC for the treatment of multiple sclerosis (MS). AzaC treatment of myelodysplastic syndrome often improves the autoimmune disorders accompanying it. Another epigenetic drug, decytabin, was effective in EAE, suggesting that AzaC might behave similarly. Earlier, we found that AzaC improves aggrecan-induced arthritis in mice, further supporting our hypothesis. Methods: AzaC was tested in an animal model of MS: MOG35–55-induced experimental allergic encephalomyelitis (EAE) in B6 mice. In addition to AzaC, its ester, prodrug triacetyl-5-azacytidine (TAC), reported earlier to exhibit improved stability and oral bioavailability, was also tested. Results: In our proof-of-concept experiment, i.p. administered AzaC ameliorated EAE. Then, we demonstrated that oral TAC is as effective as the positive comparator fingolimod. Next, we demonstrated that sub-optimal doses of oral TAC and fingolimod positively synergize. Importantly, the myelosuppression induced by TAC was not worse than that of the gold-standard fingolimod. Conclusions: Ours is the first study reporting the therapeutic activity of oral TAC. Both AzaC and TAC were effective in EAE; therefore, they can be proposed for the treatment of remitting–relapsing MS and possibly other autoimmune diseases. In addition, combination treatment with TAC and fingolimod might allow for lower individual drug doses, thus offering an alternative when side effects limit the use of current multiple sclerosis drugs.
- 15 April 2025
- Published by MDPI AG in Therapeutics
- Vol. 2 (2) , 6
Open AccessTriacetyl-5-Azacytidine Suppresses Experimental Allergic Encephalomyelitis (EAE) in Mice
Background/Objectives: The epigenetic drug 5-azacytidine (AzaC) is being used for the treatment of myeloproliferative diseases. It has multiple immunomodulating activities: it enhances the activity of Treg cells and suppresses effector T cell proliferation and function. Our aim was to repurpose AzaC for the treatment of multiple sclerosis (MS). AzaC treatment of myelodysplastic syndrome often improves the autoimmune disorders accompanying it. Another epigenetic drug, decytabin, was effective in EAE, suggesting that AzaC might behave similarly. Earlier, we found that AzaC improves aggrecan-induced arthritis in mice, further supporting our hypothesis. Methods: AzaC was tested in an animal model of MS: MOG35–55-induced experimental allergic encephalomyelitis (EAE) in B6 mice. In addition to AzaC, its ester, prodrug triacetyl-5-azacytidine (TAC), reported earlier to exhibit improved stability and oral bioavailability, was also tested. Results: In our proof-of-concept experiment, i.p. administered AzaC ameliorated EAE. Then, we demonstrated that oral TAC is as effective as the positive comparator fingolimod. Next, we demonstrated that sub-optimal doses of oral TAC and fingolimod positively synergize. Importantly, the myelosuppression induced by TAC was not worse than that of the gold-standard fingolimod. Conclusions: Ours is the first study reporting the therapeutic activity of oral TAC. Both AzaC and TAC were effective in EAE; therefore, they can be proposed for the treatment of remitting–relapsing MS and possibly other autoimmune diseases. In addition, combination treatment with TAC and fingolimod might allow for lower individual drug doses, thus offering an alternative when side effects limit the use of current multiple sclerosis drugs.
- 14 May 2019
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 44 (6) , 777-785
Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers
Sirolimus (Rapamune®) exhibits low bioavailability, high variability and moderate food effect following oral administration. This makes therapeutic blood monitoring of sirolimus concentrations necessary for kidney transplant patients. Furthermore, reaching therapeutic blood sirolimus concentrations in renal cancer patients was found to be challenging when the marketed drug was administered alone. A novel, nano-amorphous formulation of the compound was developed and its pharmacokinetic properties were investigated in a dose escalation study in a first-in-human clinical trial. The effect of food at the highest dose on the pharmacokinetic parameters was also assessed.
- 14 May 2019
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 44 (6) , 777-785
Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers
Sirolimus (Rapamune®) exhibits low bioavailability, high variability and moderate food effect following oral administration. This makes therapeutic blood monitoring of sirolimus concentrations necessary for kidney transplant patients. Furthermore, reaching therapeutic blood sirolimus concentrations in renal cancer patients was found to be challenging when the marketed drug was administered alone. A novel, nano-amorphous formulation of the compound was developed and its pharmacokinetic properties were investigated in a dose escalation study in a first-in-human clinical trial. The effect of food at the highest dose on the pharmacokinetic parameters was also assessed.
- 1 March 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 129, 79-86
Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate
- 1 March 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 129, 79-86
Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate
- 25 January 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (2) , 90
Preparation, Pre-clinical and Clinical Evaluation of a Novel Rapidly Absorbed Celecoxib Formulation
Celecoxib (Celebrex®) is the only widely used NSAID that selectively inhibits the COX-2 isoenzyme. Celebrex® is absorbed slowly in the fasted state and food intake further delays absorption. In this...
- 25 January 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (2) , 90
Preparation, Pre-clinical and Clinical Evaluation of a Novel Rapidly Absorbed Celecoxib Formulation
Celecoxib (Celebrex®) is the only widely used NSAID that selectively inhibits the COX-2 isoenzyme. Celebrex® is absorbed slowly in the fasted state and food intake further delays absorption. In this...
- 12 November 2018
- Published by American Chemical Society (ACS) in Journal of Chemical & Engineering Data
- Vol. 63 (12) , 4453-4458
Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate
- 12 November 2018
- Published by American Chemical Society (ACS) in Journal of Chemical & Engineering Data
- Vol. 63 (12) , 4453-4458
Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate
- 3 August 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 80 (4) , 723-728
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect
Zytiga (abiraterone acetate, AA) is known to exhibit very low bioavailability and a significant positive food effect in men. The unfavorable pharmacokinetic properties are attributed to the inadequate and variable dissolution of the compound. Using a continuous flow precipitation technology, a novel AA formulation has been developed with improved solubility and dissolution characteristics. The current study was performed to evaluate the pharmacokinetics and safety of this novel formulation in healthy volunteers.
- 3 August 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 80 (4) , 723-728
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect
Zytiga (abiraterone acetate, AA) is known to exhibit very low bioavailability and a significant positive food effect in men. The unfavorable pharmacokinetic properties are attributed to the inadequate and variable dissolution of the compound. Using a continuous flow precipitation technology, a novel AA formulation has been developed with improved solubility and dissolution characteristics. The current study was performed to evaluate the pharmacokinetics and safety of this novel formulation in healthy volunteers.
- 1 August 2015
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 94, 135-140
Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method
- 1 August 2015
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 94, 135-140
Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method
- 1 April 2014
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 86 (3) , 361-368
Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties
- 1 April 2014
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 86 (3) , 361-368
Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties